title: Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori.
abstract: BACKGROUND
  A previous study showed that 14 days of qid bismuth-based triple therapy with tetracycline 500 mg, metronidazole 250 mg and colloidal bismuth subcitrate 120 mg resulted in excellent Helicobacter pylori eradication rates (89.5%). The present study looked at a shorter treatment period by adding omeprazole and by reducing the dose of tetracycline.
  
  
  METHODS
  One hundred sixty-one patients with H pylori confirmed by histology and (13)carbon urea breath test were included in the study. They were treated for seven days with bismuth subcitrate 120 mg plus metronidazole 250 mg plus tetracycline 250 mg qid plus omeprazole 20 mg bid (OBMT). Patients were 18 to 75 years of age and had dyspepsia with or without a history of peptic ulcer. Patients with irritable bowel syndrome, active ulcer or previous attempt at eradication, or those who had used antibiotics or antiulcer drugs in the previous 30 days were excluded. Eradication was determined by two (13)carbon urea breath tests done one and three months, respectively, after treatment. Strains with minimal inhibitory concentrations of 8 microg/mL or higher were considered to be resistant to metronidazole.
  
  
  RESULTS
  The overall per protocol eradication rate was 84%-89.5% in metronidazole-sensitive and 70.8% in metronidazole-resistant strains. Modified intent-to-treat analysis resulted in a 80% eradication rate--82.5% in metronidazole-sensitive and 66.7% in metronidazole-resistant strains. Only one patient discontinued treatment because of adverse events.
  
  
  CONCLUSIONS
  The OBMT regimen used in this study is safe and effective against metronidazole-sensitive H pylori strains.
authors.affiliation: Centre Hospitalier de l'Université de Montréal, Hôpital St-Luc, 1058 St-Denis, Montréal, Quebec H2X 3J4, Canada. lahaier@odyssee.net
authors.forename: R
authors.initials: R
authors.lastname: Lahaie
authors.forename: A
authors.initials: A
authors.lastname: Farley
authors.forename: C
authors.initials: C
authors.lastname: Dallaire
authors.forename: A
authors.initials: A
authors.lastname: Archambault
authors.forename: C A
authors.initials: CA
authors.lastname: Fallone
authors.forename: T
authors.initials: T
authors.lastname: Ponich
authors.forename: R
authors.initials: R
authors.lastname: Hunt
authors.forename: M
authors.initials: M
authors.lastname: Oravec
authors.forename: P
authors.initials: P
authors.lastname: Whitsitt
authors.forename: S V
authors.initials: SV
authors.lastname: Van Zanten
authors.forename: N
authors.initials: N
authors.lastname: Marcon
authors.forename: R
authors.initials: R
authors.lastname: Bailey
authors.forename: A
authors.initials: A
authors.lastname: Dumont
authors.forename: B
authors.initials: B
authors.lastname: Nguyen
authors.forename: S
authors.initials: S
authors.lastname: Desrochers
authors.forename: J
authors.initials: J
authors.lastname: Spénard
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011336:Probability; D013752:Tetracycline / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D008795:Metronidazole; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole